Nivolumab Combined with Ipilimumab
Updated Data From Clinical Trials on Nivolumab/Ipilimumab in Advanced Melanoma - The ASCO Post
Metastatic Melanoma Clinical Trial Results | OPDIVO® (nivolumab)
Nivolumab: targeting PD-1 to bolster antitumor immunity | Future Oncology
Melanoma Adjuvant Clinical Trial Results | OPDIVO® (nivolumab)
CheckMate 511 NIVO/IPI Dosing - Capsule Summary Slidesets - Skin Cancer - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options
Adjuvant Nivolumab Continues to Provide Superior Recurrence-Free
Melanoma Adjuvant Clinical Trial Results | OPDIVO® (nivolumab)
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study - European Journal of Cancer
Long-Term Data Reinforce Standard of Care in Unresectable Melanoma | MedPage Today
Nivolumab and Relatlimab for Advanced Melanoma - NCI
Melanoma Adjuvant Clinical Trial Results | OPDIVO® (nivolumab)
BMS' Opdivo/Yervoy improves long-term survival for melanoma patients - PharmaTimes
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma | Nature Medicine
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma | Nature Medicine
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology
Melanoma Adjuvant Clinical Trial Results | OPDIVO® (nivolumab)
VisualAbstract: Nivolumab plus ipilimumab is safe and effective for the treatment of advanced melanoma (CheckMate 218) | 2 Minute Medicine
Nivolumab Bests Ipilimumab as Adjuvant Therapy in Resected Melanoma | ESMO
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma | NEJM
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172) - European Journal of Cancer
Metastatic Melanoma Clinical Trial Results | OPDIVO® (nivolumab)
Perspective on the Use of Nivolumab Combined with Ipilimumab For Advanced Melanoma | SCF - Skin Cancer Foundation Provider
